EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Beyond the Label: The Unseen Risks of Fungal Contamination in Medications

P. D. Adokeme, S. A. Assor, C. G. Ikechi-Nwogu

Scientia Africana · 29.04.2026 · 25 (2) · 95-102

DOI: 10.4314/sa.v25i2.10 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scientia Africana, online erschienen am 29.04.2026. Verfasst von P. D. Adokeme und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fungal contamination in pharmaceutical drugs poses unseen risks to public health especially for people with weakened immune systems. Despite their importance, pharmaceutical drugs can get contaminated with fungi during storage, altering their properties. Dispensable pharmaceutical drugs were gathered from pharmacies in Choba, Obio-Akpor Local Government Area of Rivers State. Fungal isolates were collected and morphologically identified. Internal Transcribed Spacer 4 and 5 (ITS-4 and 5) molecular markers were used to characterize the DNA of the most prevalent fungal isolates, RCBBR-P13 and SR-2A. The morphological results indicated that RCBBR-P13 and SR-2A isolates were Aspergillus fumigatus and Aspergillus niger. Each isolate's DNA had a molecular weight of more than 600 base pairs. According to sequence similarity, the isolate's DNA sequence was 99% identical to that of A. niger isolate MG596642.1 and 100% identical to that of A. fumigatus isolate ICL-PG-FUN-SG-7. According to these results, Aspergillus species is a prevalent fungal pathogen found in pharmaceutical items. A phylogenetic tree revealed relationships between isolates. The presence of A. fumigatus and A. niger in drugs poses infection risks, alter drug efficacy and safety, leading to treatment failures or adverse effects. Study underscores need for stricter manufacturing, storage, and distribution practices to prevent fungal contamination. Findings may prompt regulatory reviews and guidelines for pharmaceutical quality control in Nigeria and guide future research on risks and mitigation. This report of Aspergillus species in pharmaceutical drugs, highlights the need for vigilance in ensuring medication safety and provides groundwork for assessing risks of fungal-contaminated medications.

Zitieren

APA

Adokeme, P. D., Assor, S. A., & Ikechi-Nwogu, C. G. (2026). Beyond the Label: The Unseen Risks of Fungal Contamination in Medications. Scientia Africana, 25(2), 95-102. https://doi.org/10.4314/sa.v25i2.10

Vancouver

Adokeme PD, Assor SA, Ikechi-Nwogu CG. Beyond the Label: The Unseen Risks of Fungal Contamination in Medications. Scientia Africana. 2026;25(2):95-102. doi:10.4314/sa.v25i2.10

BibTeX
@article{Adokeme2026,
  author = {Adokeme, P. D. and Assor, S. A. and Ikechi-Nwogu, C. G.},
  title = {Beyond the Label: The Unseen Risks of Fungal Contamination in Medications},
  journal = {Scientia Africana},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {95--102},
  doi = {10.4314/sa.v25i2.10}
}
Kostenlos starten →